NTC acquires ocular antibiotic products portfolio

Privately-held Italian pharmaceutical company NTC has acquired some Novartis ocular antibiotic products from Swiss pharma giant Novartis (NOVN: VX), including broad spectrum antibiotic therapies to treat eye diseases.

Countries covered under the agreement, financial terms of which have not been disclosed, include Spain, Portugal, Italy and Poland.

"This agreement reinforces our industrial development program in ophthalmology," says Riccardo Carbucicchio, chief executive and chairman of NTC, adding: "In fact, we are strongly committed to making new therapeutic solutions available in ophthalmology, to enable specialists to offer drugs, medical devices and supplements to improve the compliance of their patients. Many of our new products are designed and developed with the help of expert ophthalmologists, with whom we have established important research and development collaborations. Furthermore, we firmly believe in the importance of having in our portfolio consolidated and successful products, alongside new offerings, that maintain a fundamental role in the treatment of eye diseases."